MCID: PMP014
MIFTS: 51

Pemphigoid

Categories: Immune diseases, Skin diseases

Aliases & Classifications for Pemphigoid

MalaCards integrated aliases for Pemphigoid:

Name: Pemphigoid 12 36 32

Classifications:



External Ids:

Disease Ontology 12 DOID:0080841
KEGG 36 H01650
ICD10 32 L12 L12.9

Summaries for Pemphigoid

KEGG : 36 Pemphigoid diseases are group of autoimmune blistering disorders of the skin and mucous membranes characterized by autoantibodies directed against structural proteins of the dermal-epidermal junction that clinically can manifest with urticarial lesions, tense blisters, and erosions which may involve the mucous membranes. Diseases in this group include bullous pemphigoid (BP), dermatitis herpetiformis, mucous membrane pemphigois, linear IgA bullous dermatosis, herpes gestationis, and epidermolysis bullosa acquisita. BP is the most common acquired bullous autoimmune dermatosis disease. It is primarily a disease of the elderly with an equal incidence in men and women. The clinical characteristics are the formation of tense blisters and pruritic urticarial erythema. Histopathologically, subepidermal blister formation associated with eosinophil infiltration is commonly observed in BP. The main autoantigens targeted by BP autoantibodies are hemidesmosomal transmembrane collagen XVII (COL17, also known as BP180/BPAG2) and the intracytoplasmic plakin family protein BP230. Most of these antibodies belong to the immunoglobulin G class. Diagnosis of BP relies on the clinical and histological aspects, but the most reliable clues are given by direct and indirect immunofluorescence. Three types of drugs, with distinct mechanisms of action, are used to treat BP: anti-inflammatory drugs, drugs designed to reduce the production of pathogenic antibodies, and treatments that increase the elimination of pathogenic antibodies from the serum of patients, such as high-dose intravenous immunoglobulin (IVIG) therapy and therapeutic plasma exchange.

MalaCards based summary : Pemphigoid is related to pemphigoid gestationis and ocular cicatricial pemphigoid. An important gene associated with Pemphigoid is DST (Dystonin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Prednisone and Omalizumab have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and t cells, and related phenotypes are growth/size/body region and digestive/alimentary

Disease Ontology : 12 An autoimmune disease of skin and connective tissue that is characterized by subepidermal blistering especially in the lower abdomen, groin, and flexor surfaces of the extremities, creating tense blisters that do not break easily.

Wikipedia : 74 Pemphigoid is a group of rare autoimmune blistering diseases of the skin, and mucous membranes. As its... more...

Related Diseases for Pemphigoid

Diseases related to Pemphigoid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 872)
# Related Disease Score Top Affiliating Genes
1 pemphigoid gestationis 32.5 IL5 DST COL17A1 CCL11
2 ocular cicatricial pemphigoid 32.1 TGFB1 ITGB4 ITGA6 IL4 HLA-DQB1
3 lichen planus pemphigoides 31.8 ITGB4 DST COL17A1
4 pemphigus 31.7 TNF IL4 HLA-DQB1 DST COL17A1
5 cicatricial pemphigoid 31.6 ITGB4 ITGA6 IL4 IL1B HLA-DQB1 DST
6 epidermolysis bullosa acquisita 31.5 ITGB4 DST COL17A1
7 epidermolysis bullosa 31.3 ITGB4 ITGA6 DST COL17A1
8 linear iga disease 31.0 ITGB4 DST COL17A1
9 bullous pemphigoid 30.8 TNF ITGB4 ITGA6 IL5 IL4 IL13
10 bullous skin disease 30.7 IL5 DST COL17A1
11 epidermolysis bullosa, junctional, non-herlitz type 30.6 ITGB4 DST COL17A1
12 paraneoplastic pemphigus 30.6 HLA-DQB1 DST COL17A1
13 pompholyx 30.5 DST COL17A1
14 cytokine deficiency 30.5 IL5 IL13
15 erythema multiforme 30.4 TNF IL5 IL4 IFNG
16 junctional epidermolysis bullosa 30.4 ITGB4 ITGA6 DST COL17A1
17 dermatitis herpetiformis 30.4 TNF IL5 IL4 HLA-DQB1 CCL11
18 herpes zoster 30.2 TNF IFNG COL17A1
19 subcorneal pustular dermatosis 30.1 DST COL17A1
20 urticaria 30.1 TNF IL5 IL4 IL13
21 exanthem 30.1 TNF IL1B IFNG
22 epidermolysis bullosa simplex 30.1 ITGB4 DST COL17A1
23 gingivitis 30.0 TNF IL4 IL1B IFNG
24 stevens-johnson syndrome/toxic epidermal necrolysis 30.0 IL5 IL13 IFNG
25 atopic keratoconjunctivitis 30.0 IL5 IL4 IFNG
26 hypereosinophilic syndrome 30.0 IL5 IL4 IL13 IFNG CCL11
27 nocardiosis 29.9 TNF IFNG
28 poliomyelitis 29.9 TNF IL4 IFNG
29 cutaneous t cell lymphoma 29.8 IL5 IL4 IFNG
30 chickenpox 29.8 TNF IL4 IFNG
31 pyloric atresia 29.8 ITGB4 ITGA6 COL17A1
32 lichen planus 29.7 TNF IL4 IL1B IFNG DST COL17A1
33 alopecia 29.7 TNF IL4 IL1B IFNG
34 acute graft versus host disease 29.7 TNF IL4 IFNG
35 chronic urticaria 29.6 TNF IL4 IL13
36 gingival recession 29.6 TNF IL1B
37 myasthenia gravis 29.6 TNF IL4 IFNG HLA-DQB1
38 conjunctivitis 29.6 TNF IL5 IL4 IL13 IFNG CCL11
39 epidermolysis bullosa junctionalis with pyloric atresia 29.6 ITGB4 ITGA6 DST COL17A1
40 graft-versus-host disease 29.6 TNF IL1B IFNG HLA-DQB1
41 neutropenia 29.5 TNF IL4 IL1B IFNG
42 basal cell carcinoma 29.5 TNF IL1B DST COL17A1
43 psoriasis 29.5 TNF IL5 IL4 IL1B IL13 IFNG
44 localized scleroderma 29.5 TNF TGFB1 IL4 IL13
45 contact dermatitis 29.5 TNF IL5 IL4 IL1B IFNG
46 autoimmune hepatitis 29.4 TNF IL4 HLA-DQB1
47 lepromatous leprosy 29.4 TNF IL4 IFNG
48 purpura 29.4 TNF IL4 IL1B IFNG
49 graves' disease 29.4 IL4 IL13 IFNG HLA-DQB1
50 thyroiditis 29.4 TNF IL4 IL1B IFNG

Graphical network of the top 20 diseases related to Pemphigoid:



Diseases related to Pemphigoid

Symptoms & Phenotypes for Pemphigoid

MGI Mouse Phenotypes related to Pemphigoid:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.1 HLA-DQB1 IFNG IL13 IL1B IL4 IL5
2 digestive/alimentary MP:0005381 10.09 HLA-DQB1 IFNG IL13 IL4 IL5 ITGA6
3 hematopoietic system MP:0005397 10.07 CCL11 HLA-DQB1 IFNG IL13 IL1B IL4
4 immune system MP:0005387 10.06 CCL11 HLA-DQB1 IFNG IL13 IL1B IL4
5 craniofacial MP:0005382 10 IFNG IL1B IL4 ITGA6 ITGB4 TGFB1
6 integument MP:0010771 9.86 IFNG IL13 IL1B IL4 ITGA6 ITGB4
7 neoplasm MP:0002006 9.63 IFNG IL1B IL5 ITGA6 TGFB1 TNF
8 nervous system MP:0003631 9.61 HLA-DQB1 IFNG IL13 IL1B IL4 ITGA6
9 respiratory system MP:0005388 9.32 CCL11 HLA-DQB1 IFNG IL13 IL4 IL5

Drugs & Therapeutics for Pemphigoid

Drugs for Pemphigoid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Omalizumab Approved, Investigational Phase 4 242138-07-4
3
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
4
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
5
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
6 Immunoglobulins Phase 4
7 Antibodies Phase 4
8 Hormone Antagonists Phase 4
9 Hormones Phase 4
10 glucocorticoids Phase 4
11 Antineoplastic Agents, Hormonal Phase 4
12 Anti-Asthmatic Agents Phase 4
13 Respiratory System Agents Phase 4
14 Immunoglobulins, Intravenous Phase 4
15 Immunoglobulin E Phase 4
16 Vitamins Phase 4
17 Hydrocortisone hemisuccinate Phase 4
18 Calcium, Dietary Phase 4
19 Hydrocortisone 17-butyrate 21-propionate Phase 4
20 Calciferol Phase 4
21
Calcium Nutraceutical Phase 4 7440-70-2 271
22
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
23
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
24 Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
25
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
26
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
27
Levoleucovorin Approved, Investigational Phase 2, Phase 3 68538-85-2 149436
28
Triamcinolone Approved, Vet_approved Phase 2, Phase 3 124-94-7 31307
29
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
30
Mycophenolic acid Approved Phase 2, Phase 3 24280-93-1 446541
31
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5
32
Dapsone Approved, Investigational Phase 2, Phase 3 80-08-0 2955
33
rituximab Approved Phase 3 174722-31-7 10201696
34
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
35 Benralizumab Approved, Investigational Phase 3 1044511-01-4
36
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
37
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
38
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
39
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7
40
Cortisone Experimental Phase 2, Phase 3 53-06-5 222786
41 Antimetabolites Phase 3
42 Rho(D) Immune Globulin Phase 3
43 gamma-Globulins Phase 3
44 Alkylating Agents Phase 3
45 Gastrointestinal Agents Phase 2, Phase 3
46 Immunosuppressive Agents Phase 2, Phase 3
47 Antiemetics Phase 2, Phase 3
48 Vitamin B Complex Phase 2, Phase 3
49 Folate Phase 2, Phase 3
50 Vitamin B9 Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 56)
# Name Status NCT ID Phase Drugs
1 Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid in Patients With Bullous Pemphigoid Unknown status NCT02360202 Phase 4 Clobetasol Propionate cream treatment
2 An Open Label Case Series on the Effects of Xolair (Omalizumab) in Bullous Pemphigoid Completed NCT00472030 Phase 4 Omalizumab;prednisone
3 Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid Not yet recruiting NCT03926377 Phase 4
4 Comparison of Monotherapy With Protracted Superpotent Topical Steroids to Superpotent Topical Steroids Associated With Methotrexate in Bullous Pemphigoid Unknown status NCT02313870 Phase 3 clobetasol propionate + Methotrexate;clobetasol propionate alone
5 Pharmacokinetics Study of Mycophenolic Acid in Patients With an Autoimmune Bullous Dermatose, Pemphigus or Cicatricial Pemphigoid. Completed NCT02993133 Phase 3 Cellcept® in autoimmune bullous dermatoses
6 NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Bullous Pemphigoid Unresponsive to Corticosteroids: Randomized, Double-Blind, Placebo Control,Parallel Assignment Study(Phase III) Completed NCT01408550 Phase 3 NPB-01;Placebo
7 Assessment of Rituximab Efficiency and Tolerance in Treatment of Bullous Pemphigoid. Completed NCT00525616 Phase 3 Mabthera
8 Randomized Double Blind Double Dummy Control Trial Comparing the Safety and Efficacy of Rituximab Versus Oral Cyclophosphamide in Severe Forms of Mucous Membrane Pemphigoid Recruiting NCT03295383 Phase 3 Rituximab 1g IV;Cyclophosphamide 50Mg Oral Tablet;Placebo of Rituximab;Placebo Oral Tablet
9 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid Recruiting NCT04206553 Phase 2, Phase 3 dupilumab;Matching Placebo;Oral corticosteroids (OCS)
10 Clinical Evaluation of New Treatment Strategy of Mucous Membrane Pemphigoid Using Large Dose of Prednisolone Plus Intra-lesional of Triamcinolone Acetonide Followed by Combination of Mycophenolate Mofetil, Dapsone and Low Dose Prednisolone Active, not recruiting NCT04744623 Phase 2, Phase 3 large dose of prednisolone plus intra-lesional of Triamcinolone Acetonide followed the systemic combination of mycophenolate mofetil (MMF), dapsone and low dose prednisolone in treatment of MMP
11 A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study to Investigate the Use of Benralizumab as a Treatment Option for Patients With Bullous Pemphigoid (FJORD) Not yet recruiting NCT04612790 Phase 3
12 An Open-Label Study to Evaluate the Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid Not yet recruiting NCT04128176 Phase 3 Rituximab combined with Omalizumab
13 Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid. An Open Prospective Study Unknown status NCT00802243 Phase 2 leflunomide
14 Anti-IL-5 Therapy in Bullous Pemphigoid. Randomized, Placebo-controlled, Double-blind Study Evaluating the Effect of Anti-IL-5 Therapy in Patients With Bullous Pemphigoid. Completed NCT01705795 Phase 2 Mepolizumab (a-IL-5 antibody);Placebo
15 Phase I/II Clinical Trial Evaluating Rituximab in Ocular Cicatricial Pemphigoid Completed NCT00584935 Phase 1, Phase 2 Rituximab
16 The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
17 Rituximab in the Treatment of Patients With Bullous Pemphigoid Completed NCT00286325 Phase 1, Phase 2 Rituximab
18 A Comparison of Oral Methylprednisolone Plus Azathioprine or Mycophenolate Mofetil for the Treatment of Bullous Pemphigoid Completed NCT00431119 Phase 2 Azathioprine or Mycophenolate mofetil
19 A Phase IIa Open-label Single Arm Study of Safety and Efficacy of rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects Completed NCT04035733 Phase 2
20 NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Bullous Pemphigoid Unresponsive to Corticosteroids: Randomized, Double-Blind, Placebo Control,Parallel Assignment Study(PhaseⅡ). Completed NCT00809822 Phase 2 NPB-01;Placebo
21 Ixekizumab in the Treatment of Bullous Pemphigoid Completed NCT03099538 Phase 2 Ixekizumab
22 An Open-Label, Proof of Concept Study Designed to Evaluate the Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Newly Diagnosed, Moderate to Extensive Bullous Pemphigoid Completed NCT02226146 Phase 2
23 Dexamethasone Solution and Dexamethasone in Mucolox™ for the Treatment of Oral Inflammatory Ulcerative Diseases Recruiting NCT04540133 Phase 2 dexamethasone 0.5mg/5ml solution;dexamethasone 0.5mg/5ml solution in Mucolox™
24 Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody Recruiting NCT04563923 Phase 2 Avdoralimab (IPH5401)
25 Efficacy and Safety of Ustekinumab in Bullous Pemphigoid Recruiting NCT04117932 Phase 2 Ustekinumab
26 Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid Recruiting NCT04499235 Phase 2 Mometasone furoate;AKST4290;Placebo
27 A Phase 2, Multicentre, Single Arm, Pilot Study to Assess the Efficacy and the Safety of 150 mg Twice a Day Oral DF2156A in Patients With Active Bullous Pemphigoid. Terminated NCT01571895 Phase 2 DF2156A
28 A Randomized, Open-Label, Controlled Trial of Topical AC-203 in Subjects With Bullous Pemphigoid Terminated NCT03286582 Phase 2 AC-203 1% Topical Ointment;Clobetasol 0.05% Topical Ointment
29 A Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of QGE031 in the Treatment of Patients With Bullous Pemphigoid With Disease Refractory to Oral Steroid Treatment Terminated NCT01688882 Phase 2 QGE031;Placebo
30 Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Withdrawn NCT02126020 Phase 1, Phase 2 topical infliximab
31 The Improvement of Limbal Epithelial Culture Technique for the Treatment of Unilateral Limbal Insufficiency by Using Collagenase to Isolate Limbal Stem Cells Unknown status NCT02202642 Phase 1
32 Phase I Study of Vorinostat in Combination With Niacinamide, and Etoposide for the Treatment of Patients With Relapsed and Refractory Lymphoid Malignancies Completed NCT00691210 Phase 1 Vorinostat;Niacinamide;Etoposide
33 Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study. Active, not recruiting NCT02502903 Phase 1 BIV009
34 Serum Free Fatty Acids Desaturase Activity Indices in Sera of Patients on Long-term High-dose Corticosteroid Treatment Unknown status NCT02872584 Prednisone
35 Explore the Mechanisms of Pruritus in Bullous Pemphigoid Patients During Remission Unknown status NCT01265082
36 Genetic Susceptibility and Influence of the Microbiomae in Bullous Pemphigoid Unknown status NCT02874079
37 Multicenter Prospective Observational Study Assessing Outcomes, Adverse Events, Treatment Patterns and Related Costs in Patients Diagnosed With Bullous Pemphigoid Unknown status NCT02837965 treatment with topical superpotent corticosteroid therapy;treatment with systemic therapy (methotrexate);treatment systemic therapy (prednisone);treatment with systemic therapy (prednisone);treatment with systemic therapy (doxycycline)
38 Dipeptidyl Peptidase-IV Inhibitors, Risk Factor for Development of Bullous Pemphigoid? : Multicenter Retrospective Study in France and Switzerland Unknown status NCT03636763 data report
39 An Open Randomized Comparative Trial of Four Different Dressings for Cutaneous Coverage in Pemphigus and Pemphigoid Unknown status NCT02365675
40 Interest of Dosage of Anti-PB230, Anti-PB180 and Cytokines for Monitoring of Patients Suffering From Bullous Pemphigoid Completed NCT02883894
41 Comparison of Two Therapeutic Strategies of Dermoval in Treatment of Bullous Pemphigus Completed NCT00213421 Dermoval
42 Pruritus and Pemphigoid in Nursing Home Patients Completed NCT02823067
43 Evaluation of Cytokines and Immunoglobulins in Serum and Blister Fluids Appeared Before Treatment and Subsequently Under Treatment in Bullous Pemphigoid Completed NCT03856840
44 Clinical Characteristics of Pruritus and Evaluation of Quality of Life in Patients With Bullous Pemphigoid Completed NCT03272958
45 Impact of Neurological Diseases on the Prognosis of Bullous Pemphigoid: A Retrospective Study of 178 Patients Completed NCT03320798
46 The Effects of Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis Recruiting NCT03839069
47 Proteomic and Metabolomic Lacrimal Fingerprint in Diverse Pathologies of the Ocular Surface Recruiting NCT04198740
48 Clinical, Biological and Histological Characteristics of Bullous Pemphigoid Induced by antiPD-1/PDL-1 Therapy: A National Retrospective Cohort Study Recruiting NCT04641884
49 Prevalence and Clinical Severity of Autoimmune Blistering Diseases Recruiting NCT02753777
50 The Association of Bullous Pemphigoid With Dipeptidyl-peptidase 4 Inhibitors: Α Ten-year Prospective Observational Study. Active, not recruiting NCT04469582

Search NIH Clinical Center for Pemphigoid

Genetic Tests for Pemphigoid

Anatomical Context for Pemphigoid

MalaCards organs/tissues related to Pemphigoid:

40
Skin, Eye, T Cells, Breast, Neutrophil, B Cells, Thyroid

Publications for Pemphigoid

Articles related to Pemphigoid:

(show top 50) (show all 6800)
# Title Authors PMID Year
1
A case of mucous membrane pemphigoid with anti-BP230 autoantibodies alone. 61
32970829 2021
2
Subjective and Objective Measurements of Sinonasal Manifestations in Patients With Autoimmune Disorders. 61
32324298 2021
3
Laryngeal Pemphigoid Evolution and Response to Treatment. 61
33583674 2021
4
Bullous pemphigoid without detection of autoantibodies in a patient with psoriasis under ustekinumab. 61
32743906 2021
5
Bullous pemphigoid in adolescence, a rare demographic. 61
32935855 2021
6
Classifying the severity of bullous pemphigoid disease. 61
33599983 2021
7
Clinical characteristics and outcomes of bullous pemphigoid patients with versus without oral prednisolone treatment. 61
33600037 2021
8
Bullous pemphigoid in a young male during treatment with adalimumab. 61
32981042 2021
9
Bullöses Pemphigoid ohne Autoantikörper bei einem Psoriasis-Patienten unter Ustekinumab-Therapie. 61
33586890 2021
10
Immunomodulator Galectin-9 is Increased in Blood and Skin of Patients with Bullous Pemphigoid. 61
33606034 2021
11
Infantile bullous pemphigoid after meningococcal B vaccine. 61
33527376 2021
12
Management of immune checkpoint inhibitor-induced bullous pemphigoid. 61
32428613 2021
13
Treatment of Bullous Pemphigoid in People Aged 80 Years and Older: A Systematic Review of the Literature. 61
33230804 2021
14
Two Cases of Porokeratosis with MVD Mutations, Complicated by Bullous Pemphigoid. 61
33554266 2021
15
Dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid: A comparative study of 100 patients with bullous pemphigoid and diabetes mellitus. 61
33543537 2021
16
Case of bullous pemphigoid induced by apatinib mesylate. 61
33534135 2021
17
A Convolutional Neural Network architecture for the recognition of cutaneous manifestations of COVID-19. 61
33604961 2021
18
The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study. 61
33573656 2021
19
Serum thymus and activation-regulated chemokine (TARC/CCL17) may be useful to predict the disease activity in patients with bullous pemphigoid. 61
32761977 2021
20
A new eruption of bullous pemphigoid within psoriatic plaques following cyclosporine withdrawal. 61
33490340 2021
21
Dupilumab use in dermatologic conditions beyond atopic dermatitis - a systematic review. 61
31693426 2021
22
Ocular Cicatricial Pemphigoid, Sjögren's Syndrome, and Hashimoto's Thyroiditis as a Multiple Autoimmune Syndrome: A case report. 61
33601905 2021
23
Aquaporins and diseases pathogenesis: From trivial to undeniable involvements, a disease-based point of view. 61
33559160 2021
24
Rituximab as an Adjuvant Rescue Treatment for Ocular Cicatricial Pemphigoid. 61
33591038 2021
25
Expression of PD-1 and Tim-3 is increased in skin of patients with bullous pemphigoid and pemphigus vulgaris. 61
32596926 2021
26
BP180 Is a Prognostic Factor in Head and Neck Squamous Cell Carcinoma. 61
33517320 2021
27
Using electronic health records to inform trial feasibility in a rare autoimmune blistering skin disease in England. 61
33541270 2021
28
Bullous Pemphigoid Associated with Anti-programmed Cell Death Protein 1 and Anti-programmed Cell Death Ligand 1 Therapy: A Review of the Literature. 61
33426566 2021
29
Interleukin-31, a Potent Pruritus-Inducing Cytokine and Its Role in Inflammatory Disease and in the Tumor Microenvironment. 61
33559859 2021
30
Paraneoplastic pemphigus associated with small lymphocytic lymphoma: A case report. 61
33466152 2021
31
Ultra-high frequency ultrasound in the differential diagnosis of oral pemphigus and pemphigoid: An explorative study. 61
33405267 2021
32
Case of bullous pemphigoid under treatment with adalimumab for hidradenitis suppurativa. 61
33502014 2021
33
Images of the month: Gliptin-induced bullous pemphigoid. 61
33479092 2021
34
[Bullous pemphigoid over a surgical wound. An emerging complication in the elderly?] 61
32972767 2021
35
Essential oils as potential triggers for bullous pemphigoid? A report of two patients. 61
33495145 2021
36
Epidermolysis bullosa acquisita: the most frequent pemphigoid disease in patients with dermal binding autoantibodies by indirect immunofluorescence microscopy on human salt-split skin in Tehran, Iran. 61
33497481 2021
37
Diagnostic Value and Practicability of Serration Pattern Analysis by Direct Immunofluorescence Microscopy in Pemphigoid Diseases. 61
33491096 2021
38
Case of anti-laminin γ1 pemphigoid associated with ulcerative colitis and acquired perforating dermatosis. 61
32981121 2021
39
Case of pemphigoid with immunoglobulin G antibodies to BP180 C-terminal domain and laminin-γ1 (p200) developed after pneumococcal vaccination. 61
32974956 2021
40
The incidence of bullous pemphigoid continues to increase in England. 61
32538459 2021
41
Immunoglobulin M pemphigoid. 61
33453342 2021
42
Incidence of pemphigoid diseases in Northern Germany in 2016 - first data from the Schleswig-Holstein Registry of Autoimmune Bullous Diseases. 61
33428263 2021
43
Bullous pemphigoid is a common associated disorder with acquired haemophilia A. 61
32949372 2021
44
Bullous pemphigoid induced by ustekinumab: a case report. 61
33355283 2021
45
Intravenous Immunoglobulin Therapy for Gestational Pemphigoid Refractory to Conventional Treatment. 61
32986975 2021
46
False-Negative Rate of Direct Immunofluorescence on Lower Extremities in Bullous Pemphigoid. 61
32618708 2021
47
Bullous pemphigoid and dipeptidyl peptidase-4 inhibitors: the importance of the pharmacotherapeutic history. 61
32198232 2021
48
Association between dipeptidyl peptidase-4 inhibitors and risk of bullous pemphigoid in patients with type 2 diabetes: A population-based cohort study. 61
33232759 2021
49
Diagnosis and treatment of bullous pemphigoid that developed twice after total knee replacement arthroplasty: a case report. 61
33509137 2021
50
Gemeinsames Auftreten von bullösem Pemphigoid und Psoriasis mit ausgeprägten neutrophilen Infiltraten. 61
33491892 2021

Variations for Pemphigoid

Expression for Pemphigoid

Search GEO for disease gene expression data for Pemphigoid.

Pathways for Pemphigoid

Pathways related to Pemphigoid according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.96 TNF TGFB1 IL5 IL4 IL1B IL13
2
Show member pathways
13.79 TNF TGFB1 ITGB4 ITGA6 IL5 IL4
3
Show member pathways
13.65 TNF TGFB1 IL5 IL4 IL1B IL13
4
Show member pathways
13.48 TNF TGFB1 ITGB4 ITGA6 IL5 IL4
5
Show member pathways
13.38 TNF TGFB1 ITGB4 ITGA6 IL5 IL4
6
Show member pathways
13.34 TNF TGFB1 IL5 IL4 IL1B IL13
7
Show member pathways
13.29 TNF TGFB1 IL5 IL4 IL1B IL13
8 12.86 TGFB1 ITGA6 IL5 IL4 IL13 IFNG
9
Show member pathways
12.76 TNF TGFB1 IL5 IL4 IL1B IL13
10
Show member pathways
12.75 TGFB1 ITGB4 ITGA6 DST COL17A1
11
Show member pathways
12.66 ITGB4 ITGA6 DST COL17A1
12
Show member pathways
12.62 TNF TGFB1 IL5 IL4 IL1B IFNG
13
Show member pathways
12.59 TNF IL4 IFNG HLA-DQB1
14
Show member pathways
12.56 TNF IL5 IL4 IL13
15 12.54 TNF IL4 IL1B IFNG
16
Show member pathways
12.54 TNF TGFB1 IL5 IL4 IL1B IL13
17
Show member pathways
12.41 IL5 IL4 IL13 IFNG
18
Show member pathways
12.36 TNF IL5 IL4 IL1B IL13 IFNG
19
Show member pathways
12.34 TNF IL4 IL1B IFNG
20 12.29 TNF TGFB1 IL1B IFNG HLA-DQB1
21
Show member pathways
12.29 TNF TGFB1 IL5 IL4 IL1B IL13
22
Show member pathways
12.28 TNF TGFB1 ITGA6 IL4 IL1B IFNG
23
Show member pathways
12.27 TNF TGFB1 ITGB4 ITGA6
24
Show member pathways
12.24 TNF IL4 IL1B IFNG CCL11
25 12.08 TNF TGFB1 IL1B IFNG
26 12.07 TNF TGFB1 IL4 IL1B IFNG
27 12.06 TNF IL1B IFNG
28 12.04 TNF TGFB1 IL4 IL1B IL13 CCL11
29 12.03 TNF IL5 IL4 IFNG
30
Show member pathways
12 IL5 IL1B IL13
31 11.98 TNF TGFB1 IL1B IFNG
32 11.97 TNF ITGA6 IL5 IL4 IL1B HLA-DQB1
33
Show member pathways
11.96 IL4 IL1B IFNG
34 11.93 TGFB1 IL1B IFNG
35 11.93 TNF TGFB1 IL1B IFNG HLA-DQB1
36
Show member pathways
11.92 TGFB1 IL4 IL1B IFNG
37 11.9 TNF TGFB1 IL1B
38 11.87 IL5 IL4 IL13 IFNG
39 11.86 TNF TGFB1 IFNG
40
Show member pathways
11.83 TNF TGFB1 IL1B IFNG
41
Show member pathways
11.83 TNF IL5 IL4 IFNG
42 11.81 TNF TGFB1 IL1B IFNG
43 11.81 TNF IL5 IL4 IL1B IL13 IFNG
44 11.76 TNF TGFB1 IL5 IL4
45
Show member pathways
11.69 TNF IL1B IFNG
46 11.68 IL5 IL4 CCL11
47 11.65 TNF TGFB1 IFNG
48 11.62 TNF TGFB1 IL1B IFNG
49 11.6 TNF IL4 IL1B IL13
50 11.58 TNF TGFB1 IL1B IFNG

GO Terms for Pemphigoid

Cellular components related to Pemphigoid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.81 TNF TGFB1 IL5 IL4 IL1B IL13
2 extracellular space GO:0005615 9.61 TNF TGFB1 IL5 IL4 IL1B IL13
3 basement membrane GO:0005604 9.43 ITGB4 DST COL17A1
4 hemidesmosome GO:0030056 8.8 ITGB4 DST COL17A1

Biological processes related to Pemphigoid according to GeneCards Suite gene sharing:

(show top 50) (show all 60)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 10.1 TNF TGFB1 IL5 IL4 IL1B
2 positive regulation of cell proliferation GO:0008284 10.04 TGFB1 IL5 IL4 IL1B IFNG
3 MAPK cascade GO:0000165 9.97 TNF TGFB1 IL5 IL1B
4 positive regulation of gene expression GO:0010628 9.97 TNF TGFB1 IL4 IL1B IL13 IFNG
5 extracellular matrix organization GO:0030198 9.96 TNF ITGB4 ITGA6 COL17A1
6 positive regulation of protein phosphorylation GO:0001934 9.92 TNF TGFB1 IL1B IFNG
7 positive regulation of cell migration GO:0030335 9.91 TGFB1 ITGA6 IL4 IL1B CCL11
8 response to virus GO:0009615 9.89 TNF IFNG CCL11
9 positive regulation of DNA-binding transcription factor activity GO:0051091 9.88 TNF IL5 IL1B
10 inflammatory response GO:0006954 9.88 TNF TGFB1 IL5 IL1B IL13 CCL11
11 integrin-mediated signaling pathway GO:0007229 9.87 ITGB4 ITGA6 DST
12 positive regulation of inflammatory response GO:0050729 9.86 TNF IL1B IFNG
13 positive regulation of interleukin-6 production GO:0032755 9.85 TNF IL1B IFNG
14 cellular response to mechanical stimulus GO:0071260 9.84 TGFB1 IL1B IL13
15 response to wounding GO:0009611 9.84 TGFB1 ITGB4 DST
16 regulation of insulin secretion GO:0050796 9.83 TNF IL1B IFNG
17 positive regulation of protein complex assembly GO:0031334 9.8 TNF TGFB1 IFNG
18 positive regulation of phagocytosis GO:0050766 9.78 TNF IL1B IFNG
19 extrinsic apoptotic signaling pathway GO:0097191 9.77 TNF TGFB1 IFNG
20 positive regulation of nitric oxide biosynthetic process GO:0045429 9.77 TNF IL1B IFNG
21 positive regulation of B cell proliferation GO:0030890 9.76 IL5 IL4 IL13
22 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.76 TNF IL4 IL13 IFNG
23 protein kinase B signaling GO:0043491 9.74 TNF TGFB1 IL1B
24 positive regulation of amyloid-beta formation GO:1902004 9.73 TNF IFNG
25 positive regulation of immunoglobulin production GO:0002639 9.73 IL5 IL13
26 lipopolysaccharide-mediated signaling pathway GO:0031663 9.73 TNF TGFB1 IL1B
27 cellular response to organic cyclic compound GO:0071407 9.73 TNF TGFB1 ITGA6 IL1B
28 myeloid dendritic cell differentiation GO:0043011 9.72 TGFB1 IL4
29 positive regulation of histone acetylation GO:0035066 9.72 TGFB1 IL1B
30 positive regulation of glial cell proliferation GO:0060252 9.72 TNF IL1B
31 negative regulation of lipid catabolic process GO:0050995 9.72 TNF IL1B
32 astrocyte activation GO:0048143 9.72 TNF IFNG
33 regulation of regulatory T cell differentiation GO:0045589 9.71 TGFB1 IFNG
34 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.71 TNF IL1B
35 macrophage activation GO:0042116 9.71 IL4 IL13
36 positive regulation of neuroinflammatory response GO:0150078 9.7 TNF IL1B
37 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.7 TNF TGFB1
38 negative regulation of neurogenesis GO:0050768 9.7 TNF IL1B CCL11
39 cytokine-mediated signaling pathway GO:0019221 9.7 TNF TGFB1 IL5 IL4 IL1B IL13
40 negative regulation of amyloid-beta clearance GO:1900222 9.69 TNF IFNG
41 positive regulation of podosome assembly GO:0071803 9.69 TNF IL5
42 positive regulation of MHC class II biosynthetic process GO:0045348 9.69 IL4 IFNG
43 skin morphogenesis GO:0043589 9.68 ITGB4 ITGA6
44 regulation of establishment of endothelial barrier GO:1903140 9.68 TNF IL1B
45 positive regulation of mast cell degranulation GO:0043306 9.67 IL4 IL13
46 nail development GO:0035878 9.65 ITGB4 ITGA6
47 vascular endothelial growth factor production GO:0010573 9.65 TNF IL1B
48 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.65 TNF IL1B IFNG
49 positive regulation of cellular respiration GO:1901857 9.64 IL4 IFNG
50 neuroinflammatory response GO:0150076 9.63 IL4 IFNG

Molecular functions related to Pemphigoid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.23 TNF TGFB1 IL5 IL4 IL1B IL13
2 insulin-like growth factor I binding GO:0031994 9.16 ITGB4 ITGA6
3 neuregulin binding GO:0038132 8.96 ITGB4 ITGA6

Sources for Pemphigoid

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....